Related Experiment Videos

Chagas' disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice

A R Teixeira1, M A Calixto, M L Teixeira

  • 1Laboratory for Multidisciplinary Research in Chagas' Disease, Faculty of Health Sciences, University of Brasilia, Brazil.

Mutation Research
|March 1, 1994
PubMed

Insights

Certain nitroimidazole and nitrofuran drugs used to treat parasitic infections may cause cancer. Specifically, 2-nitroimidazole derivatives were linked to a higher incidence of lymphomas in mice, potentially posing risks for human patients.

Area of Science:

  • Pharmacology
  • Toxicology
  • Oncology

Background:

  • Antitrypanosomal nitroimidazoles and nitrofurans are used to treat parasitic infections.
  • The carcinogenic potential of these compounds, particularly 2-nitroimidazole derivatives, requires thorough investigation.

Purpose of the Study:

  • To assess the carcinogenic activity of antitrypanosomal 2-nitroimidazole, 5-nitroimidazole, and 5-nitrofuran derivatives.
  • To investigate the relationship between drug potency, administration duration, and lymphoma development.

Main Methods:

  • Female Swiss mice were administered 2-nitroimidazole, 5-nitroimidazole, and 5-nitrofuran derivatives intraperitoneally.
  • Incidence of growths, histologic type, and survival rates were analyzed.
  • Statistical significance was determined using alpha = 0.05.

Main Results:

  • A significantly higher incidence of lymphoblastic lymphoma was observed in mice treated with 2-nitroimidazole derivatives compared to 5-nitro derivatives.
  • Lymphoma development was more strongly associated with drug potency than administration duration.
  • The 2-nitro derivative that induced the highest lymphoma incidence significantly decreased mouse survival, likely due to efficient enzymatic nitro group reduction.

Conclusions:

  • The indiscriminate use of these nitroarene derivatives for treating Trypanosoma cruzi infections in humans may lead to a significant number of lymphomas.
  • Further research is warranted to evaluate the long-term safety and carcinogenic risks of these antitrypanosomal agents.

Related Concept Videos